TABLE 1.

The specific metabolites of PF in the treatment of cholestasis.

No.	HMDB ID	Compound name	KEGG ID	Change trend
				Model group a	PF group b
1	HMDB0000951	Taurochenodesoxycholic acid	C05465	↑	↓
2	HMDB0011662	3-Beta-hydroxy-4-beta-methyl-5-alpha-cholest-7-ene-4-alpha-carboxylate	C04840	↑	↓
3	HMDB0000138	Glycocholic acid	C01921	↑	↓
4	HMDB0001008	Biliverdin	C00500	↑	↓
5	HMDB0000698	Lithocholic acid glycine conjugate	C15557	↑	↓
6	HMDB0013626	Adrenoyl ethanolamide	C13829	↑	↓
7	HMDB0004158	Urobilinogen	C05791	↑	↓
8	HMDB0011637	Taurohyocholate	C15516	↑	↓
9	HMDB0001085	Leukotriene B4	C02165	↑	↓
10	HMDB0002178	3a,7a,12a-Trihydroxy-5b-cholestanoyl-CoA	C05448	↓	↑
11	HMDB0004158	Urobilinogen	C05790	↑	↓
12	HMDB0005084	N-Acetyl-leukotriene E4	C11361	↑	↓
13	HMDB0002012	Ubiquinone-1	C00399	↓	↑
14	HMDB0001023	4,4-Dimethylcholesta-8,14,24-trienol	C11455	↓	↑
15	HMDB0004085	Tuberculostearic acid	C16794	↑	↓
16	HMDB0005896	4-Hydroxyestradiol	C14209	↑	↓
17	HMDB0002200	Leukotriene E4	C05952	↑	↓
18	HMDB0000036	Taurocholic acid	C05122	↑	↓
19	HMDB0012639	20-Hydroxy-leukotriene E4	C03577	↑	↓
20	HMDB0002596	Deoxycholic acid 3-glucuronide	C03033	↑	↓
21	HMDB0000138	Glycocholic acid	C01921	↑	↓
22	HMDB0000036	Taurocholic acid	C05122	↑	↓
23	HMDB0011637	Taurohyocholate	C15516	↑	↓
24	HMDB0000086	Glycerophosphocholine	C00670	↑	↓
25	HMDB0002639	Sulfolithocholylglycine	C11301	↑	↓

^aChange trends compared with the normal.

^bChanges trend compared with the model group. The levels of differential metabolites were marked with downregulated (↓) and upregulated (↑).